by Lee Jungyun
Published 15 Apr.2022 16:25(KST)
[Asia Economy Reporter Lee Jung-yoon] Samsung Biologics announced on the 15th that the payment for the registered common stock rights offering worth 3.2008 trillion KRW has been completed.
The number of shares to be issued is 5,009,000, and the new shares are scheduled to be listed on the 28th.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.